Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<ns4:p><ns4:bold>Background:</ns4:bold> To restrict trial endpoints to infections acquired after vaccination in Phase IIb trials of candidate malaria vaccines, participants are treated with anti-malarial drugs to clear existing infections. Anti-malarial drugs with a long half-life may inhibit the acquisition of new infections. This study evaluated the effects of three anti-malarial drug regimens on the clearance of existing infections and acquisition of new infections.</ns4:p><ns4:p> <ns4:bold>Methods:</ns4:bold> An open-label randomised controlled trial (MalPaC) was conducted between November 2013 and February 2014. Ninety adults were randomised 1:1:1 to receive one of three treatments: atovaquone/proguanil and artesunate (AP+AS); artesunate (AS); or sulphadoxine-pyrimethamine, artesunate, and primaquine (SP+AS+PQ). Parasite monitoring was determined over 84-day follow-up by assessing<ns4:italic> Plasmodium falciparum</ns4:italic> positivity by 18s qPCR, live and sexual stage parasites by RT-PCR, and recrudescence of infections by<ns4:italic> msp2</ns4:italic> genotyping.</ns4:p><ns4:p> <ns4:bold>Results</ns4:bold>: At enrolment, parasite prevalence by qPCR was 44% (40/90, day 0), which fell to 10% (9/90, day 16), then rose to almost the initial rates by day 84 (39%, 35/90). Individuals treated with AS and SP+AS+PQ were more likely to have higher qPCR positive rates compared to participants treated with AP+AS in the immediate post-treatment phase (days 16-28) (OR=7.7 [95%CI 4.6-12.8] p&lt;0.0005 and OR=4.2 [95%CI 2.6-6.8] p&lt;0.0005, respectively). In the immediate post-treatment phase, qPCR positivity was less likely associated with evidence of live parasites and gametocytaemia. Prevalence of “old”, “new” or “undetectable” infections did not differ significantly over time or drug regimen. However, participants on the AP+AS drug regimen were less likely to have parasite infection recrudescence compared to participants treated with AS and SP+AS+PQ.</ns4:p><ns4:p> <ns4:bold>Conclusion:</ns4:bold> Falciparum DNA remained detectable by PCR post-treatment with incomplete parasite clearance regardless of drug regimen. Though AP+AS drug regimen may also have partially suppressed the acquisition of new infections during post-treatment follow-up.</ns4:p><ns4:p> Trial registration: Pan African Clinical Trials Registry, 22nd of August 2013, <ns4:ext-link xmlns:ns3="http://www.w3.org/1999/xlink" ext-link-type="uri" ns3:href="https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=625">PACTR201309000625311</ns4:ext-link>.</ns4:p>

Original publication

DOI

10.12688/wellcomeopenres.15627.1

Type

Journal

Wellcome Open Research

Publisher

F1000 Research Ltd

Publication Date

20/02/2020

Volume

5

Pages

36 - 36